Front Row Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Front Row Advisors's XBI Position: Q1 2026 in Review
Front Row Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 20 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #489.
Front Row Advisors first reported a position in XBI in Q1 2020 and has held it in 25 quarters since. The position peaked at $3K in Q3 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Front Row Advisors held 20 shares of State Street SPDR S&P Biotech ETF worth $2.56K as of Q1 2026.
- Front Row Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #489 holding.
- Front Row Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 25 quarters since.
- Front Row Advisors's State Street SPDR S&P Biotech ETF position peaked at $3K in Q3 2021.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.